Researchers Make Stem Cell Breakthrough
Posted on: Tuesday, 20 November 2007, 21:00 CST
CHICAGO _ In an advance that could transform stem cell research and accelerate progress toward treating patients with personalized replacement tissue, American and Japanese researchers report they have reprogrammed ordinary human skin cells to behave like embryonic stem cells.
By inserting four key genes into the cells, the scientists say they created a form of stem cell that can grow into virtually any kind of tissue _ a feat that previously required destroying embryos to extract cells. The discovery may clear a path for researchers to produce stem cells more easily and without the ethical problems of approaches that destroy embryos.
Testing the cells in human patients will require overcoming many obstacles, including potential risks from the viruses the groups used to place the genes in the cells. Experts also said the method will not completely replace embryonic stem cells, which they will need at least as a "gold standard" for assessing the new cells, called induced pluripotent stem (iPS) cells.
Even so, abortion opponents were quick to embrace the technique, described in research released Tuesday by the journals Cell and Science, and hailed the results as evidence that embryo-destroying research is no longer necessary.
Many researchers normally cautious about the significance of such alternative methods said the iPS cells already have started to change their field. Dozens of labs have raced to try the technique since August 2006, when the Japanese team, led by Shinya Yamanaka of Kyoto University, demonstrated the approach using mice.
Re-programming adult cells has been the Holy Grail of the field all along, said George Daley, a researcher at the Harvard Stem Cell Institute. Like many experts, he said he was shocked the two teams appear to have reached that goal so quickly.
"It's just a spectacular, spectacular advance," Daley said. "It will change everyone's thinking about the field."
Yamanaka's success with human cells was announced by Cell at the same time a separate study on the method by University of Wisconsin-Madison researcher James Thomson appeared online in Science.
Many experts found the technique especially intriguing because in theory it could allow researchers to take a patient's cells and reprogram them to make stem cells that match his immune system. Previously scientists had proposed doing that by making embryonic clones of the patient and extracting stem cells, but that alternative was technically difficult and laden with ethical objections.
The potential of iPS cells was clear right away to Dr. Jack Kessler, a stem cell researcher and chair of neurology at Northwestern University. Kessler said his team decided to start exploring the new techniques within a week of Yamanaka's report on mice last year.
"This is groundbreaking, brilliant work," he said. "I don't care who you speak to in the field; you won't find anybody who doesn't find this exciting."
A spokeswoman for President Bush, who has restricted federal funding for work on embryonic stem cells, said Bush was "very pleased" that the studies showed how to get the capabilities of stem cells without destroying embryos.
"By avoiding techniques that destroy life, while vigorously supporting alternative approaches, President Bush is encouraging scientific advancement within ethical boundaries," said Dana Perino.
Yet study leader Thomson, who co-discovered human embryonic stem cells in 1998, said political barriers have hindered all such work and stressed that the new research would not have been possible without insights gained from embryonic cells.
"My feeling is that the political controversy set the field back about four to five years," Thomson said. He credited Bush with providing some funds for the field starting in 2001 but said Bush's funding limits "represented very bad public policy as far as I'm concerned. The field has been much slower taking off than it would have been otherwise."
Both Yamanaka and Thomson said work on iPS cells should proceed side by side with research on embryonic stem cells. But Thomson added Tuesday that if the technique proves successful enough, embryonic stem cells "will gradually be used by fewer and fewer labs."
Several experts said that in retrospect the most fundamental step forward came in Yamanaka's study last year that used mouse cells. By studying which genes are most active in mice's embryonic stem cells, his team was able to pick out four genes that seemed crucial to making stem cells so versatile that they can form most kinds of tissue. Inserting the genes in ordinary mouse cells gave them the properties of embryonic stem cells.
"That was really a fascinating piece of work, and the end of a lot of workmanlike trial and error," said Evan Snyder, director of the stem cell research center at the Burnham Institute in California.
Once the mouse result was published, teams around the world launched efforts to see if it would work with human cells. No one knew if those four genes would do the same job in both species, and in fact Thomson's group in Wisconsin wound up succeeding with a slightly different mix of genes.
In essence the groups were trying to take the ordinary cells back in time, to a point in early embryonic development when the fates of an embryo's cells are not fixed. The roots of such work can be traced to the birth in 1996 of Dolly the sheep, the first animal cloned from an adult cell.
Dolly showed that researchers could reset an adult cell's clock by placing its nucleus in an egg cell. Thomson said the challenge was to find a faster and more practical approach that could reset that clock by manipulating just a few genes.
Both teams used viruses to introduce the suite of genes into the cells. One hurdle now will be to find ways of adding the genes without viruses, or removing the viruses once they've done their work.
In addition, one of the genes the Japanese team used is also an oncogene, meaning it has been linked with certain types of cancer. Thomson's group avoided using that gene, and other researchers say they are already pursuing safer ways of making the cells.
Initial testing suggests that, like embryonic stem cells, the iPS cells can form any type of tissue. Thomson said his group likely will take a closer look at how well the cells can be coaxed into forming cardiac cells, which could be transplanted into patients with heart problems, and dopamine-producing brain cells, which might offer new treatments for Parkinson's disease.
Rev. Tadeusz Pacholczyk, director of education at the National Catholic Bioethics Center in Philadelphia, said the findings could shift the stem cell debate. "This approach provides medical advantages as well as clear moral advantages," Pacholczyk said. "That's an amazing development."
Such a response is understandable but wrong, said Snyder of the Burnham Institute. For one thing, no one even knows yet exactly why the genes inserted into the iPS cells work, or what they're doing.
He and other scientists who have backed embryonic stem cell research fear the new finding may hamper efforts to lift Bush's funding limits.
"Every time we get a headline like this, some policymakers say, `OK, now we can stop funding embryonic research, and you guys can get jobs at McDonald's,'" Snyder said. "But this means there's a whole new area of research that Congress needs to fund, and you've got to compare all the cells head to head."
Source: Chicago Tribune
Related Articles
- Thomson IP Manager 3.0(R) Revolutionizes Intellectual Property Collaboration With Exclusive Advanced Technology
- Two Stem Cells Genes Not Needed In Muscle Regeneration
- Thomson IP Management Services Deploys Black Duck Software's Protex
- SOLiD(TM) System Enables Single Cell Gene Expression Profiling to Advance Stem Cell Research
- Howlett Research Corp. Publishes New Research Report on Coral Gold Resources Ltd.
- Howlett Research Corp. Publishes New Research Report on Abcourt Mines Inc.
- Stem Cell Therapy Debate Lives On, but Research Continues to Find Effective Applications in Immune and Organ Function
- Research and Markets: 2006 Research Available On Avici, Cisco, Juniper Networks and Other Core IP Routing Products
- Stem Cell Bill Expected to Force Bush Veto
- PhereSys Therapeutics Announces Consulting Agreement With Advanced Cell & Gene Therapy, LLC
User Comments (0)

RSS Feeds